Management strategies in alcoholic liver disease

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 4, Issue 1, 2007, Pages 24-34

  Tilg, Herbert ^a   Day, Christopher P ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Alcoholic steatohepatitis; Corticosteroid; Cytokines; Fatty liver disease; Tumor necrosis factor

Indexed keywords

ACAMPROSATE; ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA TOCOPHEROL; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOTIN; COLCHICINE; COPPER; CORTICOSTEROID; DISULFIRAM; GLUCOCORTICOID; INFLIXIMAB; MANGANESE; NALTREXONE; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; PLACEBO; PREDNISONE; PROPYLTHIOURACIL; RETINOL; S ADENOSYLMETHIONINE; SELENIUM; SILYMARIN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASOCONSTRICTOR AGENT; ZINC;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOL REHABILITATION PROGRAM; ALCOHOLIC FATTY LIVER; ALCOHOLIC STEATOHEPATITIS; ALCOHOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTERIC FEEDING; GASTROINTESTINAL HEMORRHAGE; HEPATORENAL SYNDROME; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INFECTION RISK; LEUKOCYTOSIS; LIVER BIOPSY; LIVER TOXICITY; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; ORGAN DONOR; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; PSYCHOTHERAPY; PUBLIC OPINION; RELAPSE; REVIEW; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; WOUND HEALING IMPAIRMENT;

FATTY LIVER; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER DISEASES, ALCOHOLIC; LIVER TRANSPLANTATION; RECURRENCE; TEMPERANCE;

EID: 33846085495     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0683     Document Type: Review

References (72)

1. Tome S and Lucey MR (2004) Review article: Current management of alcoholic liver disease. Aliment Pharmacol Ther 19: 707-714
2. Stewart SF and Day CP (2003) The management of alcoholic liver disease. J Hepatol 38 (Suppl 1):S2-S13
3. Lieber CS et al. (1965) Effects of prolonged ethanol intake: Production of fatty liver despite adequate diets. J Clin Invest 44: 1009-1021
4. Teli MR et al. (1995) The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 22: 1714-1719
5. Tsukamoto H and Lu SC (2001) Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 15: 1335-1349
6. Powell WJ Jr and Klatskin G (1968) Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 44: 406-420
7. Moyer A et al. (2002) Brief interventions for alcohol problems: A meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations. Addiction 97: 279-292
8. Garbutt JC et al. (1999) Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA 281: 1318-1325
9. Delgrange T et al. (1992) [Effect of acute administration of acamprosate on the risk of encephalopathy and on arterial pressure in patients with alcoholic cirrhosis][French]. Gastroenterol Clin Biol 16: 687-691
10. Fuller RK et al. (1986) Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 256: 1449-1455
11. Maddrey WC et al. (1978) Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75: 193-199
12. Maddrey WC (1988) Alcoholic hepatitis: Clinicopathologic features and therapy. Semin Liver Dis 8: 91-102
13. Orrego H at al. (1987) Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 92: 208-214
14. Chedid A et al. (1991) Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol 86: 210-216
15. Carithers RL Jr et al. (1989) Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 110: 685-690
16. Mathurin P et al. (2002) Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): Individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 36: 480-487
17. McCullough AJ and O'Connor JF (1998) Alcoholic liver disease: Proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 93: 2022-2036
18. Kulkarni K et al. (2004) The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol 38: 453-459
19. Said A et al. (2004) Model for End Stage Liver Disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 40: 897-903
20. Dunn W et al. (2005) MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 41: 353-358
21. Forrest EH et al. (2005) Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 54: 1174-1179
22. Hansen J et al. (1994) The role of tumor necrosis factor-alpha in acute endotoxin-induced hepatotoxicity in ethanol-fed rats. Hepatology 20: 461-474
23. Adachi Y et al. (1995) Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 108: 218-224
24. Yin M et al. (1999) Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 117: 942-952
25. Hines IN and Wheeler MD (2004) Recent advances in alcoholic liver disease III. Role of the innate immune response in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 287: G310-G314
26. Ramond MJ et al. (1992) A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 326: 507-512
27. Imperiale TF and McCullough AJ (1990) Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 113: 299-307
28. Christensen E and Gluud C (1999) Glucocorticosteroids are not effective in alcoholic hepatitis. Am J Gastroenterol 94: 3065-3066
29. Mathurin P et al. (2003) Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 38: 1363-1369
30. Mathurin P et al. (1996) Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 110: 1847-1853
31. Dey A and Cederbaum AI (2006) Alcohol and oxidative liver injury. Hepatology 43 (Suppl 1): S63-S74
32. Sun AY et al. (2001) Ethanol and oxidative stress. Alcohol Clin Exp Res 25 (Suppl ISBRA): 237S-243S
33. Leo MA and Lieber CS (1982) Hepatic vitamin A depletion in alcoholic liver injury. N Engl J Med 307: 597-601
34. Phillips M et al. (2006) Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis-A randomised clinical trial. J Hepatol 44: 784-790
35. Cabre E et al. (1990) Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 98: 715-720
36. Cabre E et al. (2000) Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: A multicenter randomized trial. Hepatology 32: 36-42
37. Strieter RM et al. (1988) Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 155: 1230-1236
38. Akriviadis E et al. (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 119: 1637-1648
39. Iimuro Y et al. (1997) Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 26: 1530-1537
40. Tilg H and Diehl AM (2000) Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343: 1467-1476
41. Spahr L et al. (2002) Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: A randomized controlled pilot study. J Hepatol 37: 448-455
42. Tilg H et al. (2003) Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 38: 419-425
43. Naveau S et al. (2004) A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39: 1390-1397
44. Mookerjee RP et al. (2003) Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 52: 1182-1187
45. Mutimer DJ et al. (1993) Managing severe alcoholic hepatitis complicated by renal failure. Q J Med 86: 649-656
46. Ortega R et al. (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 36: 941-948
47. Orrego H et al. (1987) Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 317: 1421-1427
48. Diegelmann RF and Peterkofsky B (1972) Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc Natl Acad Sci USA 69: 892-896
49. Kershenobich D et al. (1979) Treatment of cirrhosis with colchicine. A double-blind randomized trial. Gastroenterology 77: 532-536
50. Rambaldi A and Gluud C (2001) Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. The Cochrane Database of Systematic Reviews, Issue 1, Art. No CD002148.
51. Morgan TR et al. (2005) Colchicine treatment of alcoholic cirrhosis: A randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 128: 882-890
52. Ferenci P et al. (1989) Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9: 105-113
53. Pares A et al. (1998) Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 28: 615-621
54. Mato JM et al. (1999) S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 30: 1081-1089
55. Lieber CS et al. (1994) Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 106: 152-159
56. Lieber CS et al. (2003) II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 27: 1765-1772
57. Bird GL et al. (1990) Liver transplantation in patients with alcoholic cirrhosis: Selection criteria and rates of survival and relapse. BMJ 301: 15-17
58. Neuberger J et al. (2002) Transplantation for alcoholic liver disease. J Hepatol 36: 130-137
59. Wiesner RH et al. (1997) Liver transplantation for end-stage alcoholic liver disease: An assessment of outcomes. Liver Transpl Surg 3: 231-239
60. Poynard T et al. (1994) Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls. Lancet 344: 502-507
61. Kumar S et al. (1990) Orthotopic liver transplantation for alcoholic liver disease. Hepatology 11: 159-164
62. Pageaux GP et al. (1999) Alcoholic cirrhosis is a good indication for liver transplantation, even for cases of recidivism. Gut 45: 421-426
63. Cuadrado A et al. (2005) Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 11: 420-426
64. Weinrieb RM et al. (2001) Alcoholism treatment after liver transplantation: Lessons learned from a clinical trial that failed. Psychosomatics 42: 110-116
65. Neuberger J et al. (1998) Assessing priorities for allocation of donor liver grafts: Survey of public and clinicians. BMJ 317: 172-175
66. Anand AC et al. (1997) Liver transplantation for alcoholic liver disease: Evaluation of a selection protocol. Hepatology 25: 1478-1484
67. Miguet M et al. (2004) Predictive factors of alcohol relapse after orthotopic liver transplantation for alcoholic liver disease. Gastroenterol Clin Biol 28: 845-851
68. Foster PF et al. (1997) Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation. Hepatology 25: 1469-1477
69. Veldt BJ et al. (2002) Indication of liver transplantation in severe alcoholic liver cirrhosis: Quantitative evaluation and optimal timing. J Hepatol 36: 93-98
70. Lucey MR (2002) Is liver transplantation an appropriate treatment for acute alcoholic hepatitis? J Hepatol 36: 829-831
71. DiMartini A et al. (2006) Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl 12: 813-820
72. Tome S et al. (2002) Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease. J Hepatol 36: 793-798